NeuroMDx Logo

The future of brain injury healthcare!

Mild Traumatic Brain Injury (mTBI) point-of-care diagnostic platform

Mild traumatic brain injury (mTBI) impacts millions of lives, causing impairment, disability, psychosocial complications, and economic loss.

Illustration, boy fall accident

Yet, mTBI is often not detected because sensitive diagnostic tools are lacking.​

At NeuroMDx, we envision a future where mild brain injuries are recognized timely and wherever they occured.

By merging advanced bioanalytics with innovative engineering, we are working to bring laboratory precision near patients, empowering clinicians with rapid, actionable insights that save time, reduce costs, and ultimately improve patient care and outcomes.

Brain Biomarkers

Illustration of biomarker and brain

Following the injury, biomarkers pass the blood-brain barrier and enter the blood circulation.

Only 1-2 drops of blood (finger-prick sample) are needed for detection. Thanks to a panel of biomarkers, it will be possible to increase the clinical sensitivity and specificity.

NeuroMDx solution can detect multiple biomarkers simultaneously.

Image made with BioRender

A laboratory in your hand

Illustration of NeuroMDx biosensor and cartridge

Novel detection strategy powered by a patented SR-ECLIA (spatially-resolved electro-chemiluminescence immunoassay).

Multi-biomarker detection on an electrode-based biosensor. Ultra-sensitive (low pg/mL range) for mTBI. Low-cost and scalable consumables production.

Near patients

Accurate, sensitive, and quantitative results for mTBI biomarker measurements at point-of-care.

A minimally invasive, field-deployable, compact, portable, and robust system.

Short time-to-results (< 15 min.) that may be transmitted to the hospital for improved primary diagnostics and care.

Check our scientific articles for details on our technology.

RSC – Lab on a chip

RSC Article Cover Page 2025

Engineering a diagnostic platform based on a spatially resolved electrochemiluminescence immunoassay for low-plex biomarker detection at point-of-care: mild traumatic brain injury and cardiac applications

Milica Jović, Denis Prim,
Gabriel Paciotti, Marc E. Pfeifer

12th July 2025

RSC Article Cover Page 2023

A novel point-of-care diagnostic prototype system for the simultaneous electrochemiluminescent sensing of multiple traumatic brain injury biomarkers

Milica Jović, Denis Prim, Ophélie Righini, David Tagan, Mélanie Stäuble, Marc Pignat, Steve Gallay, Martial Geiser and Marc E. Pfeifer

18th April 2023

MDPI Article Cover Page 2022

Towards a Point-of-Care (POC) Diagnostic Platform for the Multiplex Electrochemiluminescent (ECL) Sensing of Mild Traumatic Brain Injury (mTBI) Biomarkers

Milica Jović, Denis Prim,
Edis Saini and Marc Emil Pfeifer

14th February 2022

Milica Jovic Photo

Milica Jovic

PhD in Chemistry, Expert in Electrochemistry and Microfabrication Techniques​. Lead Bioassay & Biosensor Developer​. Former EPFL postdoc​.

Entrepreneurial track record as Start-up Co-Founder and CTO​.

Denis Prim Photo

Denis Prim

Bioanalytical Engineer. Analytical Chemist, Specialist in Applied Optics, System Integrator & Software Developer, Surface Chemistry Expert.

Entrepreneurial track record as Start-up Co-Founder and CEO.

Gabriel Paciotti Photo

Gabriel Paciotti

Design & System Engineering Expert. Electromechanical Systems Design, Robotics & System Integration. Demonstrator Reader & Cartridge Development. Manufacturing & Industrial Process Technology Expert.

Marc E. Pfeifer Photo

Marc E. Pfeifer

Analytical Chemist and ​Surface Chemistry Expert​.

Former research leader and project manager in a large, international IVD corporation. Regulatory affairs, as well as start-up board of directors experience.

Contact us

Logo of
HES-SO Valais-Wallis
DxS Research Group
SNSF - Bridge
The Ark
InnoSuisse

The project was born out of the Diagnostic Systems Research Group (DxS) in the Institute of Life Sciences (ILS) of the School of Engineering, HES-SO Valais-Wallis in Sion (Switzerland), and it is supported by the HES-SO, BRIDGE Discovery (SNSF), Innosuisse projects, and The Ark Foundation.

Logo of
HES-SO Valais-Wallis
DxS Research Group
SNSF - Bridge
The Ark
InnoSuisse

The project was born out of the Diagnostic Systems Research Group (DxS) in the Institute of Life Sciences (ILS) of the School of Engineering, HES-SO Valais-Wallis in Sion (Switzerland), and it is supported by the HES-SO, BRIDGE Discovery (SNSF), Innosuisse projects, and The Ark Foundation.

Aerial view of Sion and the HES-SO Valais-Wallis Energypolis Campus in Switzerland

The NeuroMDx System has not been evaluated by the FDA or other regulatory agencies.